[{"id":"269bcf7a-a222-4eb1-a733-a5c181aede05","acronym":"SURPASS-3","url":"https://clinicaltrials.gov/study/NCT05601752","created_at":"2022-11-05T15:14:24.529Z","updated_at":"2024-07-02T16:34:25.911Z","phase":"Phase 2","brief_title":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)","source_id_and_acronym":"NCT05601752 - SURPASS-3","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • BRCA • PARP1 • MAGEA4","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • BRCA • PARP1 • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 08/12/2026","primary_completion_date":" 08/12/2026","study_txt":" Completion: 08/12/2026","study_completion_date":" 08/12/2026","last_update_posted":"2024-06-14"},{"id":"74c31265-1520-4843-8d42-dcf55e82cdf5","acronym":"TSCAN-001","url":"https://clinicaltrials.gov/study/NCT05473910","created_at":"2022-07-26T17:09:59.782Z","updated_at":"2024-07-02T16:34:26.524Z","phase":"Phase 1","brief_title":"A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation","source_id_and_acronym":"NCT05473910 - TSCAN-001","lead_sponsor":"TScan Therapeutics, Inc.","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive • HLA-A positive","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive • HLA-A positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • TSC-100 • TSC-101"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-13"},{"id":"06e9e816-ed4d-495d-af8e-3454497c5c2a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00194714","created_at":"2021-01-18T00:39:44.293Z","updated_at":"2024-07-02T16:34:37.821Z","phase":"Phase 1/2","brief_title":"Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab","source_id_and_acronym":"NCT00194714","lead_sponsor":"University of Washington","biomarkers":" HER-2 • IFNG","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification • HER-2 expression • HLA-A2 positive","tags":["HER-2 • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification • HER-2 expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • HER-2/neu peptide vaccine"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 05/22/2023","study_completion_date":" 05/22/2023","last_update_posted":"2024-06-06"},{"id":"d5b7efa8-e965-442b-8575-71001ab87e87","acronym":"IGNYTE-ESO","url":"https://clinicaltrials.gov/study/NCT03967223","created_at":"2021-01-19T18:07:33.215Z","updated_at":"2024-07-02T16:35:07.685Z","phase":"Phase 2","brief_title":"Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors","source_id_and_acronym":"NCT03967223 - IGNYTE-ESO","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 08/28/2024","primary_completion_date":" 08/28/2024","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-04-25"},{"id":"81497553-3d5a-49ef-8513-cf9cb5b29947","acronym":"","url":"https://clinicaltrials.gov/study/NCT05642455","created_at":"2022-12-08T14:57:33.766Z","updated_at":"2024-07-02T16:35:07.743Z","phase":"Phase 1/2","brief_title":"SPEARHEAD-3 Pediatric Study","source_id_and_acronym":"NCT05642455","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 07/30/2038","study_completion_date":" 07/30/2038","last_update_posted":"2024-04-24"},{"id":"4317ceb2-4fba-4c3e-9e3a-12523bffaa99","acronym":"","url":"https://clinicaltrials.gov/study/NCT03132922","created_at":"2021-01-18T15:26:11.009Z","updated_at":"2024-07-02T16:35:22.736Z","phase":"Phase 1","brief_title":"MAGE-A4ᶜ¹º³²T for Multi-Tumor","source_id_and_acronym":"NCT03132922","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 05/15/2017","start_date":" 05/15/2017","primary_txt":" Primary completion: 12/27/2022","primary_completion_date":" 12/27/2022","study_txt":" Completion: 09/01/2032","study_completion_date":" 09/01/2032","last_update_posted":"2024-01-22"},{"id":"c7014e55-a452-4714-a05a-416506ea6ac3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02865135","created_at":"2021-06-30T14:52:58.308Z","updated_at":"2024-07-02T16:35:23.679Z","phase":"Phase 1/2","brief_title":"Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer","source_id_and_acronym":"NCT02865135","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • DPX-E7"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 03/30/2017","start_date":" 03/30/2017","primary_txt":" Primary completion: 10/04/2019","primary_completion_date":" 10/04/2019","study_txt":" Completion: 02/06/2023","study_completion_date":" 02/06/2023","last_update_posted":"2024-01-11"},{"id":"fd91fe18-af69-409c-a905-0f8aee67d795","acronym":"","url":"https://clinicaltrials.gov/study/NCT01130077","created_at":"2021-01-18T04:29:21.248Z","updated_at":"2024-07-02T16:35:30.493Z","phase":"Phase 1","brief_title":"A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas","source_id_and_acronym":"NCT01130077","lead_sponsor":"James Felker","biomarkers":" IFNG","pipe":" | ","alterations":" HLA-A2 positive","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-03"},{"id":"cf75cef8-fbca-4f5e-981f-7832552ff034","acronym":"","url":"https://clinicaltrials.gov/study/NCT05993299","created_at":"2023-08-15T19:10:23.528Z","updated_at":"2024-07-02T16:35:33.510Z","phase":"Phase 2","brief_title":"Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma","source_id_and_acronym":"NCT05993299","lead_sponsor":"GlaxoSmithKline","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 10/12/2022","primary_completion_date":" 10/12/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-10-16"},{"id":"32d94f8c-2556-44e6-bf8b-eb176cf4a593","acronym":"","url":"https://clinicaltrials.gov/study/NCT00066729","created_at":"2021-01-18T00:09:40.503Z","updated_at":"2024-07-02T16:35:34.801Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT00066729","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CD8 • MUC16 • CTAG1B","pipe":" | ","alterations":" HLA-A2 positive","tags":["CD8 • MUC16 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 06/23/2003","start_date":" 06/23/2003","primary_txt":" Primary completion: 05/09/2006","primary_completion_date":" 05/09/2006","study_txt":" Completion: 08/01/2013","study_completion_date":" 08/01/2013","last_update_posted":"2023-10-04"},{"id":"8bfb48a5-7a5e-4365-8828-e51c1648bb77","acronym":"ATPIC","url":"https://clinicaltrials.gov/study/NCT05867004","created_at":"2023-05-19T13:04:57.952Z","updated_at":"2024-07-02T16:35:47.091Z","phase":"","brief_title":"Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma","source_id_and_acronym":"NCT05867004 - ATPIC","lead_sponsor":"Institut Claudius Regaud","biomarkers":" CD8 • IFNG • CD4 • CD14 • CD68 • FOXP3 • IL17A","pipe":" | ","alterations":" HLA-A2 positive","tags":["CD8 • IFNG • CD4 • CD14 • CD68 • FOXP3 • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-05-26"},{"id":"6cdd3bab-2dd1-4a70-9cc4-0b496a44b196","acronym":"KSH01-TCRT","url":"https://clinicaltrials.gov/study/NCT05539833","created_at":"2022-09-14T18:56:19.768Z","updated_at":"2024-07-02T16:35:51.604Z","phase":"Phase 1","brief_title":"KSH01-TCRT Solid Tumors","source_id_and_acronym":"NCT05539833 - KSH01-TCRT","lead_sponsor":"TCRx Therapeutics Co.Ltd","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KSH01"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/19/2022","start_date":" 08/19/2022","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2023-04-03"},{"id":"acb324c0-7ea9-4e70-8f73-9c5486bc513d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00199836","created_at":"2021-01-18T00:40:44.608Z","updated_at":"2024-07-02T16:36:02.794Z","phase":"Phase 1","brief_title":"A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.","source_id_and_acronym":"NCT00199836","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CD8 • CTAG1B • CTAG2","pipe":" | ","alterations":" HLA-A2 positive","tags":["CD8 • CTAG1B • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 09/03/2003","start_date":" 09/03/2003","primary_txt":" Primary completion: 09/05/2005","primary_completion_date":" 09/05/2005","study_txt":" Completion: 06/06/2006","study_completion_date":" 06/06/2006","last_update_posted":"2022-10-10"},{"id":"9414e6bb-d90c-48a4-9277-b07aefc72016","acronym":"","url":"https://clinicaltrials.gov/study/NCT05341947","created_at":"2022-04-22T13:53:40.793Z","updated_at":"2024-07-02T16:36:11.600Z","phase":"Phase 1","brief_title":"Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma","source_id_and_acronym":"NCT05341947","lead_sponsor":"Jeremy Rudnick, M.D","biomarkers":" HER-2 • IL13RA2","pipe":" | ","alterations":" CD133 expression • HLA-A2 positive","tags":["HER-2 • IL13RA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD133 expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KROS-201"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2022-04-22"},{"id":"167a4ae9-d051-47bd-af76-6495f94636e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04634747","created_at":"2021-01-19T20:37:14.629Z","updated_at":"2024-07-02T16:36:11.770Z","phase":"Phase 2","brief_title":"Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer","source_id_and_acronym":"NCT04634747","lead_sponsor":"OncoPep, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • HLA-A2 positive","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • PVX-410"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 04/30/2022","start_date":" 04/30/2022","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2022-04-20"},{"id":"e1041808-e70d-49d7-83f7-a1e19c798274","acronym":" SPEARHEAD-2","url":"https://clinicaltrials.gov/study/NCT04408898","created_at":"2021-01-18T21:15:39.069Z","updated_at":"2024-07-02T16:36:20.662Z","phase":"Phase 2","brief_title":"SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer","source_id_and_acronym":"NCT04408898 -  SPEARHEAD-2","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tecelra (afamitresgene autoleucel)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/02/2020","start_date":" 07/02/2020","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-11-16"},{"id":"7eecebd3-1e18-42ba-ab0b-e03aa0af1da0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04464889","created_at":"2021-02-24T11:03:04.121Z","updated_at":"2024-07-02T16:36:23.275Z","phase":"Phase 1","brief_title":"HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT04464889","lead_sponsor":"Medigene AG","biomarkers":" CD8 • HLA-A","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • HLA-A2 positive","tags":["CD8 • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • HLA-A2 positive"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/02/2020","start_date":" 07/02/2020","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2021-10-08"},{"id":"ae2e73b6-13f2-48ae-bb1a-68bb1e626089","acronym":"","url":"https://clinicaltrials.gov/study/NCT02528682","created_at":"2021-01-18T12:13:35.510Z","updated_at":"2024-07-02T16:36:32.490Z","phase":"Phase 1/2","brief_title":"MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT","source_id_and_acronym":"NCT02528682","lead_sponsor":"Radboud University Medical Center","biomarkers":" ABL1 • BCR • CD8","pipe":" | ","alterations":" HLA-A2 positive","tags":["ABL1 • BCR • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 03/31/2021","study_completion_date":" 03/31/2021","last_update_posted":"2021-04-01"},{"id":"fe7a7604-ae85-4796-8014-d187449bf1e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00970203","created_at":"2021-01-29T06:59:56.961Z","updated_at":"2024-07-02T16:36:39.189Z","phase":"Phase 2","brief_title":"Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer","source_id_and_acronym":"NCT00970203","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD8 • CD4","pipe":" | ","alterations":" HLA-A2 positive","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e goserelin acetate"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 10/05/2018","primary_completion_date":" 10/05/2018","study_txt":" Completion: 10/05/2019","study_completion_date":" 10/05/2019","last_update_posted":"2020-11-03"},{"id":"ba4fe848-c072-4266-9545-62fdc19cc6db","acronym":"","url":"https://clinicaltrials.gov/study/NCT00112242","created_at":"2021-01-18T00:22:07.954Z","updated_at":"2024-07-02T16:36:44.048Z","phase":"Phase 1","brief_title":"Immunotherapy of Stage III/IV Melanoma Patients","source_id_and_acronym":"NCT00112242","lead_sponsor":"Centre Hospitalier Universitaire Vaudois","biomarkers":" CD8 • IFNG • TNFA • CTAG1B • CD4 • MLANA • CTAG2","pipe":" | ","alterations":" HLA-A2 positive","tags":["CD8 • IFNG • TNFA • CTAG1B • CD4 • MLANA • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 02/01/2004","start_date":" 02/01/2004","primary_txt":" Primary completion: 03/01/2013","primary_completion_date":" 03/01/2013","study_txt":" Completion: 03/01/2013","study_completion_date":" 03/01/2013","last_update_posted":"2020-06-18"},{"id":"980e1068-fd01-44b1-b3ab-8466fd9acc2c","acronym":"BAMC-C.2007.098","url":"https://clinicaltrials.gov/study/NCT00524277","created_at":"2021-01-18T01:53:39.730Z","updated_at":"2024-07-02T16:36:47.236Z","phase":"Phase 2","brief_title":"Vaccine Therapy in Treating Patients With Breast Cancer","source_id_and_acronym":"NCT00524277 - BAMC-C.2007.098","lead_sponsor":"San Antonio Military Medical Center","biomarkers":" HER-2 • ER • PGR • CSF2","pipe":" | ","alterations":" HER-2 amplification • HER-2 expression • HLA-A2 positive • PGR negative","tags":["HER-2 • ER • PGR • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 expression • HLA-A2 positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AE 37 • GLSI-100 • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 456","initiation":"Initiation: 01/01/2007","start_date":" 01/01/2007","primary_txt":" Primary completion: 12/31/2014","primary_completion_date":" 12/31/2014","study_txt":" Completion: 03/31/2017","study_completion_date":" 03/31/2017","last_update_posted":"2020-03-30"},{"id":"f2ad8ca0-e157-4dd9-b7a2-ab122e9573db","acronym":"DC-Ova","url":"https://clinicaltrials.gov/study/NCT00478452","created_at":"2021-01-18T01:42:30.993Z","updated_at":"2024-07-02T16:36:54.304Z","phase":"Phase 1/2","brief_title":"Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients","source_id_and_acronym":"NCT00478452 - DC-Ova","lead_sponsor":"University of Pennsylvania","biomarkers":" HER-2 • MUC16","pipe":" | ","alterations":" HLA-A2 positive","tags":["HER-2 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 08/01/2005","start_date":" 08/01/2005","primary_txt":" Primary completion: 08/01/2008","primary_completion_date":" 08/01/2008","study_txt":" Completion: 08/01/2008","study_completion_date":" 08/01/2008","last_update_posted":"2019-10-23"},{"id":"87cc5f63-a0ad-42dd-ad35-4ccea033da0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00795457","created_at":"2021-01-18T03:01:07.973Z","updated_at":"2024-07-02T16:36:56.093Z","phase":"Phase 1","brief_title":"Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas","source_id_and_acronym":"NCT00795457","lead_sponsor":"Ian F. Pollack, M.D.","biomarkers":" IFNG","pipe":" | ","alterations":" HLA-A2 positive","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 01/01/2009","start_date":" 01/01/2009","primary_txt":" Primary completion: 02/01/2013","primary_completion_date":" 02/01/2013","study_txt":" Completion: 07/01/2015","study_completion_date":" 07/01/2015","last_update_posted":"2019-08-30"},{"id":"d1de477e-4158-46d8-b4ef-18de32556c68","acronym":"","url":"https://clinicaltrials.gov/study/NCT00088413","created_at":"2021-01-18T00:15:43.686Z","updated_at":"2024-07-02T16:37:00.590Z","phase":"Phase 1/2","brief_title":"PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer","source_id_and_acronym":"NCT00088413","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CEACAM5","pipe":" | ","alterations":" MUC1 expression • HLA-A2 positive","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC1 expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukine (sargramostim) • Panvac-VF (falimarev/inalimarev)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 07/21/2004","start_date":" 07/21/2004","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 05/31/2018","study_completion_date":" 05/31/2018","last_update_posted":"2019-04-16"}]